ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is associated with immune infiltration
ADORA2B is a key oncogenic driver in HNSC, contributing to tumor proliferation, migration, and an immunosuppressive TME. Its high expression is associated with poor prognosis and reduced immunotherapy efficacy. Targeting ADORA2B may enhance therapeutic outcomes and overcome treatment resistance, highlighting its potential as a diagnostic, prognostic, and therapeutic biomarker.
Authors
- Manbo Cai (ORCID: https://orcid.org/0000-0003-0235-0111)
- Junyan He (ORCID: https://orcid.org/0000-0002-8334-3484)
- Zhe Fang (ORCID: https://orcid.org/0000-0003-2890-4557)
- Shuanghui Chen (ORCID: https://orcid.org/0009-0003-8206-0356)
- Kai Pang
- Guicheng He (ORCID: https://orcid.org/0000-0003-0680-4563)
- Pian Li
- ·阿卜杜乃比 麦迪乃
- Qiao Yang
- Yang Dong (ORCID: https://orcid.org/0000-0003-3773-9346)
Institutions
- First Affiliated Hospital of University of South China (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- University of South China (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1186/s12885-025-14102-2
- Citations
- 3
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province